- Healing The Heel
Ever wake up in the morning with excruciating heel pain as soon as your feet hit the floor? If so, you're not alone. Severe heel pain, also known as heel spur syndrome, but technically called plantar fasciitis (fashee-EYE-tiss), affects nearly 2.5 million Americans each year. But according to a new study published in the August 2006 issue of Journal of Bone and Joint Surgery, those with plantar fasciitis now have a promising treatment option. - The U.S. Food And Drug Administration Approves Actonel For Broader Use In Men With Osteoporosis
On August 11, 2006, the U.S. Food and Drug Administration (FDA) approved Actonel(R) (risedronate sodium tablets) 35 mg for treatment to increase bone mass in men with osteoporosis. FDA approval of this new indication for Actonel opens the door for more men with osteoporosis to benefit from Actonel treatment. Actonel 5 mg was approved in 2000 for use in men and women to prevent and treat certain forms of steroid-induced osteoporosis. - FDA Expands REMICADE(R) Psoriatic Arthritis Indication: Anti-TNF Shown To Inhibit Joint Damage
Centocor, Inc. announced today that the U.S. Food and Drug Administration (FDA) has extended its approval for REMICADE(R) (infliximab) for inhibiting progression of structural damage and improving physical function in patients with psoriatic arthritis, in addition to reducing signs and symptoms of active arthritis. The approval is based on one-year data from the double-blind, placebo-controlled trial IMPACT 2 and two-year data from the double-blind, placebo-controlled trial IMPACT. - Arthrosurface Launches New Product For Treatment Of Patello-Femoral Disease
Arthrosurface, Inc. (http://www.arthrosurface.com), the developer of less-invasive joint resurfacing systems, recently received FDA clearance to launch its cartilage surface implant system for the treatment of patello-femoral disease. Steve Ek, COO, offered, "This is another large market in orthopaedics that, up until now, has been ill-addressed by the existing medical device industry." - New Recommendations For Use Of Bisphosphonates In Treatment Of Multiple Myeloma: Mayo Clinic
Mayo Clinic's multiple myeloma (MM) research team has jointly issued a consensus statement regarding the use of bisphosphonates to prevent or treat bone disease in MM. Their recommendations address several controversial issues, including the type of bisphosphonate to be used and the duration of such therapy, and are available in the August issue of Mayo Clinic Proceedings. - Genzyme Files For European Approval Of Synvisc(R) In Ankle And Shoulder Indications
Genzyme Corp. (Nasdaq: GENZ) announced today that it has filed with the European authority to expand the CE mark for Synvisc(R) (hylan G-F 20) to include treatment of pain due to osteoarthritis (OA) of the ankle and shoulder. Approval of a new label will provide opportunity to broaden the use of Synvisc beyond its current European-approved use in the knee and hip to the two additional joints. - Globus Medical Launches SUSTAIN(R) O
Globus Medical, Inc., one of the ten largest spinal implant manufacturers in the US, has announced the introduction of SUSTAIN(R) O. The new addition completes Globus Medical's extensive line of spacers, which includes vertebral body replacement devices SUSTAIN Small, SUSTAIN Medium, SUSTAIN Large and SUSTAIN Arch. - COX-2 Inhibitors Were Broadly Prescribed To Reduce Gastrointestinal Toxicity Prior To The Market
Nonsteroidal antiinflammatory drugs (NSAIDs) have been the most popular treatment for arthritis - despite their association with gastrointestinal (GI) complications, including bleeding ulcers and death. When selective cyclooxygenase 2 inhibitors (coxibs) were introduced a decade ago, they were widely hailed as a gastroprotective shield for NSAID users. - IU Radiologists Evaluate Treatments For Osteoporosis Spinal Fractures
Men and women with osteoporosis-related spinal fractures are sought for an Indiana University School of Medicine Department of Radiology and the National Institutes of Health research study comparing vertebroplasty to another treatment. - Cleveland Clinic Doctors And Materials Experts To Open Materials, Medicine, And NanotechnologySummit
Renowned keynote speakers will describe the spectrum of materials-related challenges in orthopedics and spinal disorders, cardiovascular diseases, neurology and neurosurgery, and minimally invasive surgery at the upcoming Materials, Medicine and Nanotechnology Summit, to be held in Cleveland, Oct. 2-5, 2006 - Penn Orthopaedic Surgeon Wins First Annual Ladies' Home Journal Health Breakthrough Award
(Philadelphia, PA) - Mary Ann Keenan, MD, Chief of Neuro-Orthopaedics for the University of Pennsylvania Health System, has been named a recipient of the first-annual Ladies' Home Journal Health Breakthrough Awards. The award recognizes leading medical professionals who are making life-saving and life-enhancing discoveries in research, treatment and diagnostics that have significantly helped women and families - Back Pain Management Experts Raise £250,000 From The Capital Fund
The RealHealth Institute, an independent healthcare company that offers expert advice and treatment for back pain and other musculoskeletal disorders, has raised £250,000 from The Capital Fund, a £50 million venture capital fund that invests in fast-growth companies in Greater London. - Where The Patient Comes First
It's a medical scenario that's all too common: patient has health issue and makes visit to physician, who then makes diagnosis and then independent decision about patient's treatment. But a paradigm shift is taking place, where the patient is an integral part of the treatment decision-making process, according to a special editorial published in the August 2006 issue of the Journal of the American Academy of Orthopaedic Surgeons. - Osteoarthritis Initiative Releases First Data
The Osteoarthritis Initiative (OAI), a public-private partnership between the National Institutes of Health (NIH) and private industry that seeks to improve diagnosis and monitoring of osteoarthritis (OA) and foster development of new treatments, has released its first set of data. - Increased Odds Of Rheumatoid Arthritis In Women Smokers Without Genetic Risk Factor
Smoking increases the chance of developing rheumatoid arthritis in women who otherwise lack genetic risk factors for the disease, reveals research published ahead of print in the Annals of the Rheumatic Diseases. - Knee Bone Marrow Lesions May Be Hereditary
Bone marrow lesions in the knee, a cause of pain in patients with knee osteoarthritis, may be hereditary. A study published today in the journal Arthritis Research & Therapy reveals that there is a significant genetic component to the occurrence and severity of bone marrow lesions in the tibia and femur. The study also shows that bone marrow lesions are more common in men and increase with age and weight. - Humira® (adalimumab) Receives FDA Approval For Treatment Of Ankylosing Spondylitis
Abbott announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). AS is an autoimmune disease affecting the spine and large peripheral joints that causes inflammatory back pain and stiffness and also can be associated with other inflammatory diseases of the skin, eyes and intestines. - Actress And Osteoporosis Advocate Sally Field Salutes Women's Health Innovators And Encourages
In a ceremony today, at the first annual Ladies' Home Journal Health Breakthrough Awards, Sally Field, Oscar-winning actress and advocate for osteoporosis education, honored medical professionals whose breakthroughs have benefited women's health. - Genes Behind Severe Arthritis Targeted By US Grant
A Brisbane professor will jointly lead a global study to uncover the genes that cause a common form of arthritis. - Researchers Reveal How Long-term Use Of Anti-inflammatory Medication Can Cause Osteoporosis
The steroid hormones glucocorticoids (GCs) are used at high doses to treat inflammatory and immune disorders, however they prompt bone loss and can cause osteoporosis, particularly when administered for prolonged periods. In a study appearing online in July, in advance of print publication in the August issue of the Journal of Clinical Investigation, Steven Teitelbaum and colleagues from Washington University School of Medicine investigated how GCs alter the activity of the bone-forming . - Understanding What People With Arthritis Believe About Exercise
Arthritis is the leading cause of disability in the United States. In total, the treatment and toll of this progressive disease costs our country about $86 billion per year, a figure expected to rise as Baby Boomers age. Among the many approaches to disease management, exercise has been shown to reduce pain, delay disability, and improve physical function, muscle strength, and quality of life. - Portland Orthopaedics Wins US FDA Approval To Market New Primary Hips
Portland Orthopaedics Limited (ASX:PLD) has been granted US Food and Drug Administration (FDA) approval to market the company's new M-COR primary hip in the US. The company will now ramp-up its manufacturing in preparation for delivery of its extended orthopaedic range to its exclusive US distributor, Plus Orthopedics Inc. - Tanabe Seiyaku Launches New Anti-rheumatic
Tanabe Seiyaku launched Methotrexate tablets 2mg TANABE (generic name: methotrexate), an anti-rheumatic drug for the indication of rheumatoid arthritis (RA) only if there is no indication of improvement when conventional treatment therapies such as nonsteroidal anti-inflammatory agents and other anti-rheumatic agents are used, on July 21. - Lower Estrogen Levels Are A Risk Factor For Knee Osteoarthritis
Osteoarthritis, which usually develops between the ages of 40 and 50, is more prevalent in women. It is thought that sex hormones may play a role in developing the disease, since they can be involved in inflammation of the tissues affected by it. A study published in the August 2006 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis) examined estradiol, the primary estrogen in premenopausal and early perimenopausal women. - Matrilin-3 Gene Discovered To Prevent Onset Of Osteoarthritis
A gene that is associated with osteoarthritis and skeletal deformities in people has been shown to be responsible for preventing the onset of osteoarthritis in adult mice, according to a recent study led by Rhode Island Hospital. The matrilin-3 gene plays a role in early bone development, controls bone mineral density in adulthood and prevents osteoarthritis later in life - TissueGene Initiates Phase I Clinical Trial With TG-C
TissueGene, Inc., a privately- held biopharmaceutical company advancing a pipeline of promising regenerative medicine therapeutics, announced today the acceptance of the Company's Investigational New Drug application (IND), and for the initiation of its Phase I clinical trial evaluating a single dose of TG-C for the treatment of degenerative joint diseases. This clinical trial is designed to assess the safety of TG-C in patients who have opted for total knee arthroplasty. - Seikagaku To Begin Clinical Trials Of Injectable Hyaluronic Acid Gel For Knee Osteoarthritis Treatme
Seikagaku, a Tokyo company specializing in the study of intra-articular injection of hyaluronic acid, will begun conducting phase III clinical trials of Gel-200, a new hyaluronic acid gel for intra-articular injection in knee osteoarthritis patients, in the US in August. - Women Show 47 Percent Greater Persistence With Osteoporosis Drugs If Offered Monthly Tablet, Support
Women who took an osteoporosis drug once a month and received extra telephone support from trained nurses showed 47 per cent greater persistence with their drug treatment than those who took a weekly tablet, according to a study in the August issue of IJCP, the International Journal of Clinical Practice. - Mylan Announces Final Approval For Meloxicam Tablets
Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted final approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Meloxicam Tablets, 7.5 mg and 15 mg. - Knee Replacements Designed For Women :UT Southwestern Orthopaedic Surgeons First
Orthopaedic surgeons at UT Southwestern Medial Center are the first in North Texas to use knee implants specifically designed to fit a woman's anatomy.
|
